Prurigo Nodularis is skin disease that causes hard and itchy lumps on skin, which usually appears on the arms or legs. Prurigo nodularis is a rare disease and currently, the treatment of the disease is still in research and development process. Treatments may include topical, oral, and intralesional corticosteroids; phototherapy; antihistamines; anxiolytics; opiate receptor antagonists; and thalidomide.
Key players are focusing on product approvals to strengthen their position in the global Prurigo nodularis therapeutics market. For instance, in October 2020, Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its Vixarelimab drug for the treatment of pruritus associated with prurigo nodularis.
- This report provides in-depth analysis of the global prurigo nodularis therapeutics market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global prurigo nodularis therapeutics market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Bayer AG, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, VYNE Therapeutics Inc., Trevi Therapeutics Inc., Galderma SA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global Prurigo nodularis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prurigo nodularis therapeutics market.
-
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- South Africa
- Central Africa
- North Africa
-
- Bayer AG *
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline Plc.
- Johnson & Johnson Services, Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Celgene Corporation
- VYNE Therapeutics Inc.
- Trevi Therapeutics Inc.
- Galderma SA
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co. Inc.
“*” marked represents similar segmentation in other categories in the respective section.
